Safety of Xeloda in Solid Tumours

Inclusion Criteria: Metastatic Breast Cancer: * women \>=18 years of age * Patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. * Previous therapy should have included an anthracycline. * Patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. * Female patients with histopathologically proven metastatic breast cancer * Adequate bone marrow, liver, renal and cardiac functions Colon Cancer: * Patients \>18 years of age * Patients with histologicaly confirmed colon cancer * Patients with potential curative tumor resection within 8 weeks before enrolment in the study * Patients previously not treated with chemiotherapy Exclusion Criteria: Metastatic Breast Cancer: * Patients previously treated with docetaxel (Taxotere) or capecitabine (Xeloda) * Patients with contraindications for any of study drugs as listed in approved SmPC Colon Cancer: * Patients previously treated with chemiotherapy * Patients with contraindications for study drug as listed in approved SmPC